In short. Two risk sets at the same volume: the time-critical vascular emergency that belongs to any injected material, and the late nodules that cannot be dissolved.
Key points
- It is tempting to read the two risk sets and look for the safer column.
- The columns do not work that way.
- One class carries a risk that can partly be reversed and a problem that accumulates slowly; the other carries a risk of nodules that arrive unannounced and cannot be dissolved.
Both substance classes are injected, and both therefore share the risk that belongs to any injected material. Beyond that shared risk the two sets diverge: one class produces lumps that accumulate and can sometimes be dissolved, the other produces nodules that appear late and cannot. A reader here is choosing which set to accept, not which set is smaller.
The risk that is always time-critical
Material entering a blood vessel can block the supply to the tissue it feeds and, in the worst cases, to the eye. This can follow any injected material, whichever class is used. It is time-critical: severe or increasing pain, skin turning pale, dusky or mottled, or any change in vision after a treatment needs immediate assessment rather than an appointment later in the week. Every patient should be told before treatment what to watch for and who to contact at once, including out of hours.
Lumps and nodules: two different problems
A filler can cause lumps and an over-treated area, and these may partly respond to the enzyme that breaks the material down. That is a genuine option, and it is not a complete one: dissolving may be incomplete and carries its own small risk of reaction. A biostimulator causes nodules and lumps more often, and they tend to appear weeks or months later rather than immediately. There is no dissolving agent for this class, so management means treating the problem — observation, or treatment aimed at the nodule itself — rather than removing the material.
One list is not shorter than the other
It is tempting to read the two risk sets and look for the safer column. The columns do not work that way. One class carries a risk that can partly be reversed and a problem that accumulates slowly; the other carries a risk of nodules that arrive unannounced and cannot be dissolved. Different problems, of comparable seriousness, attached to different commitments.
Other problems that belong to both
Asymmetry, uneven swelling, tenderness that lasts longer than expected, and a result that does not match what was discussed can follow either class. Bruising is common and usually minor. An infection at an injection site is uncommon and needs assessment. Because the face is visible and the result is judged by the person in the mirror, dissatisfaction is itself a real outcome, and it is worth asking in advance what the plan is if you are not happy.
Know these before you are injected
- Which symptoms are an emergency — pain that increases, skin colour change, or any change in vision.
- Who to contact at once, including outside normal hours, and how to reach them.
- What can be done if a lump or nodule appears, and what cannot be done for the material you are receiving.
A clinic that cannot answer those three questions before treatment is not set up to manage its own complications. The risk sets here are different rather than unequal, and the useful preparation is not choosing the smaller one but knowing which one you are accepting.
Frequently asked questions
What are the warning signs of vascular occlusion after an injection?
Severe or increasing pain, skin turning pale, dusky or mottled, and any change in vision. These are time-critical and need immediate assessment rather than an appointment later in the week. Every patient should be told before treatment what to watch for and exactly who to contact, including outside normal hours, because the window for treating it is short.
Why do nodules follow a biostimulator more often than a filler?
Because the biostimulator works by asking your own tissue to thicken, and that process is less predictable than material placed in a known position. Nodules also appear later, weeks or months after the session, rather than immediately. A filler can produce lumps too, but they tend to appear sooner and may partly respond to the dissolving enzyme.
How are lumps managed when the material cannot be dissolved?
By treating the problem rather than removing the material: observation while it settles, or treatment aimed at the nodule itself, which is a clinical judgement about that specific lump. This is why the question worth asking before treatment is not whether nodules happen, but what the clinic does when one appears and who reviews it.
Risks & Limitations
- Neither substance class is a zero-downtime appointment; swelling and bruising are common after either.
- Any injected material can cause vascular occlusion, which is a time-critical emergency.
- A collagen biostimulator cannot be dissolved, and nodules may appear weeks or months later.
- Dissolving a hyaluronic acid filler is not a clean undo, and it may be incomplete.
When to Seek Care
- Severe or increasing pain, or skin turning pale, dusky or mottled, after an injection.
- Any change in vision, or pain around the eye — seek emergency care immediately.
- A lump or nodule that appears weeks or months after a treatment, or that is growing.
- Fever with spreading redness, warmth or discharge at an injection site.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — procedure and safety guidance
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.